Medtronic recently announced that it received clearance from the FDA and CE Mark approval for its LINQ II insertable cardiac monitor (ICM). The announcement notes that ICMs “are small, subcutaneously ...
Medtronic this week received regulatory approval for use of an implantable cardiac monitor in pediatric patients, giving doctors and parents greater peace of mind about the device's safety. On Tuesday ...
The FDA granted 510(k) clearance to Medtronic plc's (NYSE: MDT) LINQ II Insertable Cardiac Monitor (ICM) system for use in pediatric patients over the age of 2 who have heart rhythm abnormalities and ...
The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population The LINQ II system is a small (one-third the size of a AAA battery), wireless ICM ...
Medtronic plc MDT recently announced the receipt of the FDA approval and the CE Mark for its LINQ II insertable cardiac monitor (“ICM”) with remote programming. Notably, ICM is a new long-term ...
Next Generation ICM Offers Remote Programming with Improved Longevity and Enhanced Accuracy “In the current COVID-19 environment, the LINQ II system offers patients a seamless way to experience ...
The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population DUBLIN, Sept. 20, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader ...
DUBLIN, July 07, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results